Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates

Core Insights - Relay Therapeutics continues to focus on the clinical execution of RLY-2608 trials for PI3Kα-mutated breast cancer and vascular malformations, with positive progress reported [2][8] - The company appointed Lonnel Coats and Habib Dable to its Board of Directors, bringing extensive experience in biotech commercialization and late-stage development [3][4][5] - As of September 30, 2025, the company reported approximately $596 million in cash, cash equivalents, and investments, a decrease from $781 million at the end of 2024, but sufficient to fund operations into 2029 [9][18] Clinical Trials - The Phase 3 ReDiscover-2 trial of RLY-2608 combined with fulvestrant is ongoing for advanced breast cancer patients [8] - The Phase 1/2 ReDiscover trial is advancing triplet cohorts with RLY-2608, fulvestrant, and various CDK inhibitors [8] - The Phase 1/2 ReInspire clinical trial for vascular malformations is also in progress [8] Financial Performance - Research and development expenses for Q3 2025 were $68.3 million, down from $76.6 million in Q3 2024, attributed to strategic streamlining [10] - General and administrative expenses decreased to $12.1 million in Q3 2025 from $19.8 million in Q3 2024, mainly due to reduced stock compensation and employee costs [11] - The net loss for Q3 2025 was $74.1 million, or $0.43 per share, compared to a net loss of $88.1 million, or $0.63 per share, in Q3 2024 [11]